Tumour Registry Lung Cancer (TLK)

Clinical Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01192919

Enrollment

2500

Registered

2010-09-01

Start date

2010-01-31

Completion date

2016-07-31

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

bronchial carcinoma, registry, real life treatment, cohort study, NSCLC, SCLC, Germany

Brief summary

Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.

Detailed description

The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy * written informed consent * start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent

Exclusion criteria

* patients not receiving any systemic therapy

Design outcomes

Primary

Measure	Time frame
Documentation of actually used therapy forms in bronchial carcinoma requiring treatment	3 years per patient

Outcome results